Back to top
more

Integra LifeSciences (IART)

(Delayed Data from NSDQ)

$28.34 USD

28.34
446,577

-0.07 (-0.25%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $28.35 +0.01 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for IART

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Integra LifeSciences Holdings Corporation falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 309 457 513 470 199
Receivables 259 263 232 226 275
Notes Receivable 0 0 0 0 0
Inventories 390 325 317 310 316
Other Current Assets 100 117 91 231 68
Total Current Assets 1,058 1,162 1,154 1,237 858
Net Property & Equipment 340 311 312 288 337
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 46 46 57 74 13
Intangibles 2,123 2,165 2,159 1,922 1,986
Deposits & Other Assets 58 57 16 11 15
Total Assets 3,782 3,890 3,782 3,615 3,303
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 15 38 45 34 45
Accounts Payable 92 102 62 55 113
Current Portion Long-Term Debt 0 0 0 113 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 176 159 213 170 156
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 9 7 5 17 5
Total Current Liabilities 307 321 340 401 331
Mortgages 0 0 0 0 0
Deferred Taxes/Income 35 63 46 16 37
Convertible Debt 570 567 564 475 105
Long-Term Debt 915 838 937 933 1,199
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 200 139 120 187 118
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 2,194 2,085 2,098 2,100 1,887
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 1,302 1,277 1,265 1,291 1,214
Retained Earnings 947 879 699 532 399
Other Equity -15 10 -45 -74 -76
Treasury Stock 647 363 234 235 120
Total Shareholder's Equity 1,588 1,804 1,685 1,515 1,417
Total Liabilities & Shareholder's Equity 3,782 3,890 3,782 3,615 3,303
Total Common Equity 1,588 1,804 1,685 1,515 1,417
Shares Outstanding 78.10 83.60 84.70 84.20 85.80
Book Value Per Share 20.33 21.58 19.89 17.99 16.51

Fiscal Year End for Integra LifeSciences Holdings Corporation falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 309 274 309 307
Receivables NA 259 256 259 254
Notes Receivable NA 0 0 0 0
Inventories NA 390 366 354 351
Other Current Assets NA 100 131 129 117
Total Current Assets NA 1,058 1,027 1,051 1,029
Net Property & Equipment NA 340 319 318 315
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 46 56 56 45
Intangibles NA 2,123 2,103 2,137 2,150
Deposits & Other Assets NA 58 78 67 56
Total Assets NA 3,782 3,739 3,778 3,742
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 15 10 5 0
Accounts Payable NA 92 94 100 113
Current Portion Long-Term Debt NA 0 76 91 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 176 154 159 147
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 9 8 8 8
Total Current Liabilities NA 307 356 378 282
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 35 74 71 62
Convertible Debt NA 570 570 569 568
Long-Term Debt NA 915 850 765 872
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 142 153 127
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 2,194 2,160 2,094 2,067
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1 1 1 1
Capital Surplus NA 1,302 1,262 1,284 1,245
Retained Earnings NA 947 927 908 903
Other Equity NA -15 2 5 7
Treasury Stock NA 647 613 514 482
Total Shareholder's Equity NA 1,588 1,579 1,683 1,675
Total Liabilities & Shareholder's Equity NA 3,782 3,739 3,778 3,742
Total Common Equity 0 1,588 1,579 1,683 1,675
Shares Outstanding 78.60 78.10 78.10 81.40 81.90
Book Value Per Share 0.00 20.33 20.22 20.68 20.45